Alpelisib, an alpha‐selective phosphoinositide 3‐kinase (PI3K) inhibitor, gained approval for the treatment of HR + HER2− breast cancers with PIK3CA mutations, as identified through the US FDA‐approved therascreen® PIK3CA PCR companion diagnostic (CDx) test.30 This evidence concerns the gene PIK3CA and breast cancer.